Abstract | The cause of chronic pelvic pain syndrome (CPPS) has yet to be established. Since the late 1980s, cytokine, chemokine, and immunological classification studies using human samples have focused on identifying biomarkers for CPPS, but no diagnostically beneficial biomarkers have been identified, and these studies have done little to deepen our understanding of the mechanisms underlying chronic prostatic pain. Given the large number of men thought to be affected by this condition and the ineffective nature of current treatments, there is a pressing need to elucidate these mechanisms. Prostatitis types IIIa and IIIb are classified according to the presence of pain without concurrent presence of bacteria; however, it is becoming more evident that, although levels of bacteria are not directly associated with levels of pain, the presence of bacteria might act as the initiating factor that drives primary activation of mast-cell-mediated inflammation in the prostate. Mast cell activation is also known to suppress regulatory T cell (T reg ) control of self-tolerance and also activate neural sensitization. This combination of established autoimmunity coupled with peripheral and central neural sensitization can result in the development of multiple symptoms, including pelvic pain and bladder irritation. Identifying these mechanisms as central mediators in CPPS offers new insight into the prospective treatment of the disease.
Introduction
Prostatitis (inflammation of the prostate) can be categor ized into five different subsets. Of these groups, chronic pelvic pain syndrome (CPPS) is the most common, accounting for 90-95% of all prostatitis diagnoses. This syndrome is most easily distinguished from the other types of prostatitis by the lack of bacterial association with pain symptoms, which is the case for acute prostatitis (type I) and chronic bacterial prostatitis (type II).
1 CPPS is further divided by the presence or absence of inflamma tory markers in the expressed prostatic secretion (EPS) of affected patients into inflammatory CPPS (type IIIa) and noninflammatory CPPS (type IIIb), 1 respectively. Finally, the last subset of prostatic disease, asymptomatic prosta titis (type IV), 2, 3 is associated with inflammation of the prostate without the emergence of pain symptoms, and is usually diagnosed coincidentally (Box 1).
CPPS is a condition with an estimated prevalence rate of up to 15% of the male population, with most diagnoses occurring between the ages of 35-45 years. 2, 4 However, incidence varies widely between studies, ranging from 2-16% of adult men. 4, 5 Studies of large male cohorts of varying ages from Canada, 6 Australia, 7 and China 8 have revealed incidences of 3-8%, 2%, and 8.4%, respectively, with average pain scores of 8 and total index scores of approximately 16 . 9 Incidence and symptom severity might vary based on geographic location and ethnicity, but limited data currently support this theory. 10 Diagnosed by the presence of pain in the absence of bacterial infection for >3 months, CPPS has unknown, probably complex, aetiology, which has thus far ham pered efforts to determine effective treatment strategies for ameliorating pain. [11] [12] [13] The heterogeneous nature of the symptoms and the length of the disease course before detection, presentation, and diagnosis further exacerbate these issues. The complex nature of the dis ease is reflected by the vast array of studies that have been published, ranging from genomewide association studies (GWAS) to immunological, cell biological, and microbiological investigations. In this article, we collate the disparate published data, enabling a better under standing of the mechanisms behind CPPS and providing insight into ways to enhance the efficacy of treatment.
The NIHCPSI was designed to assess the symptoms and quality of life of patients with CPPS, 19 and has been shown to be an effective tool for gauging the effect of chronic pain on morbidity. 16, 20 Using this system, patients are diagnosed with CPPS when they present with peri neal or ejaculatory pain and an index score >4. However, the system is stymied by the fact that, for the most part, it is defined based on a subjective questionnaire and overall scores are determined by a cumulative scoring of symptoms that might or might not be related to one another, or indeed to the underlying causes of patho logy. 2 More recently, the UPOINT system of classifica tion was developed to guide treatment decisionmaking (Box 2). 21 Rather than grouping patients based on an aggregate score of symptoms, this system considers each group of symptoms, including urinary, 22 psychosocial, 23 organspecific, infection, neurological, and tenderness 24 symptoms, separately (Box 2). 20 The number of symptom groups involved has been shown to correlate with NIH CPSI scores, 25 and multimodal treatment of combi nations of symptom groups has been shown to result in decreased scores after 50 weeks of treatment (mean reduction of 12 points), 26 suggesting that a more individ ually tailored approach to CPPS might be more e ffective than a standardized approach. 15, 18, [27] [28] [29] [30] Another issue that has hampered research into the factors causing CPPS is the comorbidity of symptoms. 30, 31 Chronic pain syndromes such as fibromyalgia and chronic fatigue syndrome have been shown to be associ ated with CPPS, as has irritable bowel syndrome (IBS). 32 Epidemiological studies have also linked cardiovascular problems to CPPS; in one study, patients with CPPS were six times more likely than controls to have cardiovascular disease, and were also independently shown to have an increased prevalence of arterial stiffness. 33, 34 Assessment of pelvic floor tension, by monitoring the motility of muscles using ultrasonography, linked increased tension to CPPS. 35 Although there has been some interest in investigating whether pelvic floor tension acts as a causative factor or direct mediator of CPPS, its role in d etermining patient outcomes has yet to be established. 20 
Infection as an initiating factor
Distinguishing CPPS from the other types of prostatitis requires evidence of bacterial infection. [36] [37] [38] Although effective for determining patient diagnoses, pinpointing causes of disease using such definitions might not be so clear cut. Studies of the role of bacteria in disease ini tiation are emerging from our, and other, la boratories, which might be informative for future therapeutic intervention. [39] [40] [41] We isolated a strain of Escherichia coli, desig nated CP1, from the EPS of a patient with CPPS and demonstrated that it induced symptoms of pain when introduced into the prostate and urethra of nonobese diabetic (NOD) mice. 41 NOD mice are genetically dis tinct from C57BL/6 mice and have been shown to develop spontaneous chronic pain and autoimmune prostatitis over time. Upon prostatic instillation with CP1 bacteria, NOD mice developed bacterial colonization in both the bladder and the prostate, 41 resulting in chronic pain in the NOD mice that was not detectable (by behavioural tactile allodynia scoring) in C57BL/6 mice. Although the pain symptoms persisted, no bacteria were detectable 35 days after instillation with the microbe, suggesting that infection with CP1 might initiate disease in geneti cally susceptible hosts, but that fundamental changes in the immune responses of the prostate are responsible for chronic pain. 41 In agreement with this, it is interesting to note that the incidence of chronic inflammatory prostatic disease of noninfectious origin is shown to be eightfold higher than that of bacterial prostatitis. 41 Whether similar models are applicable to humans, such that early infec tion with a pathogen might cause disease but microbes are undetectable at diagnosis of CPPS, resolving the 'abacterial' definition of CPPS IIIa and IIIb categories of p rostatitis, remains to be elucidated.
In addition, the virulence of bacterial isolates was funda mental to the initiation of disease in this mouse study. 41 Phylogenetic analyses of the CP1 strain identi fied a group B1 strain of uropathogenic E. coli (UPEC), distinct in both virulence gene and fimbriae expression from the typical group B2 bacteria, which are commonly associated with acute bacterial infection of the urogenital tract. The virulence and invasiveness of CP1 was com pared with the typical cystitisrelated UPEC group B2 42 The authors demonstrated in both in vitro and in vivo systems that, although both bacteria have the same adherence capabilities, CP1 was dramatically more invasive than NU14. 41 Interestingly, when NU14 is instilled into the prostate of NOD mice, chronic pain does not develop. We are now investigating the possibil ity that instillation of nonpathogenic strains of atypical urogenital bacteria can reverse pain symptoms in murine models of CPPS. These studies are, at present, only pre liminary but seem to indicate that prostatic instillation of certain species of microbiota can reverse inflammation in the prostate and, over time, can significantly reduce pain. 43, 44 This finding is hoped to lead to the development of p robiotic treatments for CPPS in humans.
The immune responses mediating these effects, and leading to the development of pain in the CP1 model, is an area of current investigation. Another bacteria focused study recently associated Helicobacter pylori infection with CPPS, when patients with CPPS were compared with controls based on antibody sero positivity. 45 These determinants were not correlated with severity of symptoms and only a relatively small cohort of patients were recruited, so it remains to be seen whether these preliminary findings will affect the develop ment of future therapies. 34, 45, 46 The hypothesis that bacterial infection acts as the initiating factor in CPPS is further strengthened by studies demonstrating mixed t herapeutic efficacy of antibiotics. 38, 47 Immunological basis of autoimmune activation T-cell activation and CP1 infection Numerous lines of evidence and ongoing investigations underline the role of the adaptive immune response and activation of autoimmunity in the development of CPPS (Figures 1 and 2 ). Inflammation has been shown to have an important role in the development of both prostate cancer and benign prostate hyperplasia (BPH), [48] [49] [50] [51] with studies to show increased levels of the cytokines IL6, IL8, IL15, and IL17 compared with controls. 49 Generally, the prostate contains only a small number of CD3 + T cells (approximately seven per mm 2 of tissue), of which over twothirds are also CD8 + . These numbers greatly increase with age (to about 55 per mm 2 in men aged ≤50 years), correlating with increased rates of benign prostatic disease in ageing men. 49 The role of inflammation in CPPS patho genesis is being uncovered using data from both human studies and murine models. Analysis of the immunology behind the CP1 model of chronic pain has demonstrated that T cells can mediate pelvic pain in the absence of a persistent bacterial infection. 52 In a recently published article, our lab demonstrated CP1mediated activation of Th1/Th17 CD4 + Tcell response and showed that these lymphocytes were sufficient to cause pain upon adoptive transfer to naive uninfected NOD mice. 52 IL17A, a secreted effector of Th17 cells, was fundamen tal to the development of pain in the absence of IFNγ, the main effector of Th1 cells, and pain was increased in IFNγ knockout mice upon CP1 instillation. 52 These results implicate IL17A as an essential mediator in the develop ment of pain, 53, 54 without the need for intact Th1 responses. Transfer of serum from naive or infected mice did not cause increased pain responses in these mice, indi cating that, although there is a strong autoimmune com ponent to this model of CPPS (NOD background only), 55 no current evidence supports the existence of a systemic circulating antigen or activating factor in this model. 52 Murine models of prostatitis Given the diagnostic value of separating bacterial prosta titis from conditions that are not associated with persis tent infection, murine models can offer insight into the alternative mechanisms that might mediate disease pro gression. Experimental autoimmune prostatitis (EAP) has consistently been linked with underlying immune responses associated with the development of pain in mice. Indeed, this model has been used for the past 20 years to delineate possible mechanisms underlying pathogenesis in humans. 56 The EAP model of CPPS was first investigated in Wistar rats, but our lab and others use similar models in mice. 57 Using one such murine model, investigators demonstrated that a particu lar antigen, prostatic steroid binding protein (PSBP) (also known as prostatein), is capable of inducing EAP when injected with an adjuvant (Titremax® Gold, Sigma Aldrich, USA) alone, and data suggest that additional antigens might be present in rat prostate homogenates that augment these effects. [58] [59] [60] In our laboratory, we use a 1:1 ratio of rat prostate homogenate to adjuvant that is injected subcutaneously, and pain is assessed by tactile allodynia after 7 days (for up to 30 days). 57 Studies of this model in multiple mouse strains have revealed that the development of pain occurs at the highest level, without the need for a second injection of antigen and adjuvant in the NOD background. 61 NOD mice demonstrate unchecked Tcell immune responses against Bislet cells of the pancreas, resulting in the development of diabetes mellitus. 62, 63 These mice have also been shown to develop autoimmune sialitis, thyroiditis, peripheral neuropathy, systemic lupus erythematosus, and spontaneous prosta titis, and have multiple genetic abnormalities that directly affect their immune systems. Polymorphisms have been identified in IDD3, a gene that controls expression of IL2, an essential cytokine in Tcell development; alterations in the expression pattern of this gene increase the risk of Box 2 | UPOINT system ■ Urinary problems-specifically, irritative or obstructed voiding and urinary tract issues, which might be indicative of interactions between the prostate and the bladder ■ Psychosocial problems, such as clinical depression ■ Organ specificity issues-encompassing a range of problems, such as prostate tenderness and presence of leucocytes in expressed prostatic secretions ■ Infection-even in the absence of an ongoing UTI and, despite the 'abacterial' nature of type IIIa and IIIb CPPS, microbial cultures can be grown from prostatic fluid and used to determine the initiating factors of disease ■ Neurological pain outside the pelvic region-sometimes associated with systemic chronic pain syndromes, such as fibromyalgia ■ Tenderness-generally localized to pelvic floor muscles; data suggest that sexual dysfunction might be an emerging symptom of this disease autoimmunity. 63 A second mutation-in CTLA4, a nega tive regulator of Teffector cell activation-results in incorrect splicing and leads to loss of autoreactive Tcell suppression and development of immune responses against insulinproducing cells.
64 These data, combined with the high incidence of spontaneous prostatitis in NOD mice, highlight loss of T reg suppression as a p ossible key factor in the development of EAP. 63 Development of autoimmunity D3tx mice have their thymus removed 3 days after birth and develop spontaneous inflammation as a result, 65 owing, at least in part, to the absence of selftolerized T reg cells (known as natural T reg cells), 66 which form the backbone of central tolerance. 67, 68 Thymic epi thelial cells surrounding the thymus control induction of Tcell m aturation-and, therefore, the development of t olerance-by upregulating expression of the auto immune regulator (AIRE) transcription factor. 69, 70 AIRE has been shown to regulate expression of, and thus increase tolerance to, prostate antigens. 71, 72 All AIRE deficient NOD mice develop inflammation of the pros tate by 20 weeks of age, further supporting the loss of tolerance in mouse models of chronic prostatitis. 73, 74 Notably, the spontaneous inflammation observed in D3tx mice is commonly localized to the prostate, 65, 75 indicat ing that loss of tolerance to selfprostate antigens has a central role in driving CPPS development. 76 Peripheral tolerance is also regulated by inducible T reg (iT reg ) cells that mature in a tissuespecific manner in the periphery. 77 Presentation of antigen from immature dendritic cells in the periphery can induce Teffector cell activation and proliferation in the absence of an iT reg response, prompt ing autoreactive T cells to drive inflammation in an unchecked manner. 78 This activation status could explain the immune activation that is commonly seen in murine models of CPPS, with increased number of CD4 + T cells leading to increased secretion and expression of IL17 and IFNγ. Furthermore, a broad analysis of polymorphisms in a variety of immuneregulatory genes, including TGFβ, TNFα, IL10, and IL6, revealed an association between low levels of IL10 production and CPPS, implicating loss of T reg function and tolerance as key mediators of inflam mation. 79 TNFα was also shown to be closely associated with type IIIa CPPS, suggesting that this subtype might have a more proinflammatory phenotype. Failure of REVIEWS treatment with quercetin, 80 a mast cell stabilizer, in men with CPPS with a more regulatory (antiinflammatory) phenotype is associated with high IL10 and low TNFα levels, 79 an interesting observation given that IL10 can regulate and dampen mast cell activity. This finding sug gests that mast cells in these patients are already under the regulatory control of IL10, such that further stabilization of d egranulation will not ameliorate symptoms.
However, no evidence exists to support spontaneous prostate inflammation in IL10knockout mice, which suggests that, although activation of autoreactivity might drive CPPS development, mechanisms that are dis tinct from iT reg suppression via IL10 must be respon sible for maintaining tolerance in healthy individuals. Furthermore, preliminary data from our laboratory have demonstrated that IL10knockout mice develop pelvic pain in response to EAP, but instillation with the pro biotic bacteria that decreases pain in NOD mice is ineffec tive in the absence of IL10. These data demonstrate the funda mental role of IL10, not in restraining onset of auto reactivity, but rather controlling it once it has occurred (P. Thumbikat, unpublished work). (1) and promotes the secretion and activation of proinflammatory cytokines, chemokines and presentation of antigens via APCs (2). These signalling cascades result in CD4 T-cell activation, which is initially of Th1-type (IFNγ) but Th17 activation is also implicated in the pathway, possibly at later stages of chronic pain development (3), followed by a loss of IL10-secreting suppressive T reg cells and a skewing towards Th1/17 responses (4). The loss of suppression of mast cells as a result of unchecked T-cell activation then results in a positive feedback loop in the mast cell (5,6), resulting in degranulation and release of proteases such as tryptase, chymase, and allergy mediators such as histamine (7), and secretion of cytokines (such as IL6, IL17, TNFα, and IL6), resulting in the recruitment of inflammatory cells (8) and potentially disrupting the blood-brain barrier (9) and demyelinating neurons (10) . Taken together, these processes result in neuronal activation and sensitization (11) . The mast cell mediates these events and positive feedback loops enhance these processes. Further epithelial cell damage is one consequence of such increased mast cell activity (12) . Prostate antigens generated from damage to the epithelium in the presence of an activated CD4 T-cell response, with unchecked mast cell degranulation and increased numbers of CD8 T cells can result in the development of autoimmunity, which further exacerbates these mechanisms (13).
Cytokine and chemokine association
Human studies Since the late 1980s, numerous studies have aimed to establish an association between expression of certain immunomodulatory proteins and numbers of particu lar cell types in samples from men with CPPS. Analysis of these samples, which have been taken from various urogenital and systemic sources including EPS, seminal plasma, postprostaticmassage urine, and semen, has demonstrated increased levels of numerous pro inflammatory cytokines, including, IL1b, TNFα, IL6, IL8, and IgA, [81] [82] [83] [84] [85] [86] [87] as well as decreased levels of IL2R (which is involved in Tcell development) in patients with CPPS compared with controls. Studies involving multiple sample types (including EPS, postprostatic massage urine, and semen) have shown increased numbers of granulocytes, macrophages, and both acti vated T cells and B lymphocytes in the cellular infil trate of patients with CPPS. 88 Prostate inflammation has also been examined histologically, 3 with data to show increased leucocyte infiltration and increased numbers of T cells (more specifically, CD8 + T cells) compared with controls. 89 The Tcell immune response to prostate antigens has also been investigated and CD4 T cells have been shown to respond to seminal plasma from patients in two independent studies. 90, 91 Moreover, IFNγproducing Th1 cells have been identified in the peripheral blood of men with CPPS that are specific to PSA. 92, 93 High PSA levels in blood are commonly associated with prostate tissue damage and carcinogenesis. 94 A similar study identified IgA antibodies that are specific to two addi tional prostate antigens, MADPRO34 and NyCo7, in patients with CPPS. 95 These studies, and others, point to autoreactivity to prostate antigens as a potential driver of CPPS and support the existence of organresident autoreactive T cells, which become activated following an initiation event.
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MCP1 and MIP1α
Two chemokines have been associated with the develop ment and progression of pain in multiple studies of CPPS. 96 Monocyte chemotactic protein 1 (MCP1), 97 also known as chemokine CC motif ligand 2 (CCL2), 98 is a chemotactic factor that attracts monocytes and basophils to sites of inflammation and is implicated in the pathogenesis of numerous autoimmune diseases, including rheumatoid arthritis, 99 aortic aneurysms, 100 and coronary artery disease. 101 Macrophage inflamma tion protein 1α (MIP1α), 99, 102 also known as chemokine CC motif ligand 3 (CCL3), 103, 104 is a potent inducer of proinflammatory responses and has been shown to be upregulated in patients with rheumatoid arthritis, sys temic lupus erythematosus, and ulcerative colitis. Levels of both chemokines are elevated in EPS samples from men with type IIIa and type IIIb CPPS compared with those with BPH and healthy controls. 105 It was hypoth esized that, although type IIIb CPPS (noninflamma tory) is categorized as a distinct subset of disease from type IIIa, it might, in fact, represent a distinct snapshot in the natural course of the disease when inflamma tion is ongoing but neutrophilic infiltration has yet to begin. In the same study, levels of MIP1α, but not MCP1, positively correlated with National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) pain score in patients. MCP1 was, however, positively correlated with the number of white blood cells in EPS samples, 105 indicating that, although levels of both chemo kines are increased in CPPS samples, each chemo kine might have distinct effects in terms of m ediating different symptoms of CPPS. 106 Another, morerecent, study from our laboratory also investigated CCL2 and CCL3 as potential biomarkers for CPPS using the murine EAP model. This study assessed the source, nature, and kinetics of chemokine expression and the phenotype of the associated immune infiltrate. 107 The results highlighted important roles for CCL2 and CCL3 in the pathogenesis of pelvic pain in EAP. Increases in CCL2 in prostate tissue were shown at the mRNA level at day 5 and day 20 after EAP; CCL3 increases were observed at day 20. Prostatic epithelial cells expressed the highest levels of CCL2 and CCL3, and were identified as the main source of both chemo kines in EAPtreated prostates. 107 Expression levels of these cytokines were significantly elevated in the stroma of EAPtreated prostate tissue compared with control tissue. These differences were confirmed using immunohistochemical analysis, which demonstrated increased expression of CCL2 and CCL3 in the epi thelial compartment and increased expression of another chemo kine, CCL12, in the stroma. 107 The effect of these expression changes on cellular infiltrate and numbers of various cell types was also examined; CD4 T cells were decreased at days 5 and 10, but increased at day 20, CD8 T cells were decreased at each time point after day 0, mast cells were increased at days 5 and 10, macro phage and neutrophils increased at day 10, and B cells increased at days 5 and 10. 107 Although a plethora of studies have attempted to define a biomarker for CPPS, few have used the resulting data to delineate a functional consequence for altered levels of certain cytokines or chemokines. However, the investigators in this study were able to demonstrate the functional consequences of changing the cellular milieu of mice undergoing EAP. Currently, studies are underway to identify the role of these chemokines in mediating neuroinflammation and neuropathic pain in murine models of CPPS.
Numerous studies using highthroughput arrays to measure cytokine and chemokine levels in EPS samples from patients with CPPS are underway. One such pre liminary study from our laboratory has revealed posi tive correlations between levels of a known mediator of Tcell immunity, IL7, with each of the three metrics used to categorize symptoms in patients, including the pain subscale, urinary subscale, and quality of life. Expression levels of this cytokine are currently being investigated in various mouse models of prostatitis (P. Thumbikat, unpublished work), 108 hopefully leading to a greater understanding of how the cytokine and chemokine milieu leads to progression of disease.
Mast cells
Tryptase and cellular function Mast cells have become a major focus of current research, with proposed roles as the main mediator and effector cells in disease progression from initiation to break ing of tolerance, neuronal activation, and, eventually, sensitization. 109, 110 Mast cells are derived from CD34 + haematopoietic precursor cells in bone marrow; they circulate as immature cells, only fully maturing once they are resident at a specific tissue or site, where they become activated. This process suggests a tissuespecific or organspecific cell phenotype. 111 Mast cells are also thought to be the first line of defence against infection by microbes and are usually located in (or near to) blood or lymphatic vessels and nerves.
110,111 They demonstrate both protective and pathological effects in a context dependent manner, with roles in wound healing, angio genesis, and inflammation. 110, 111 Crosslinking of their IgE receptor leads to cell sensitization (as seen in con ditions such as asthma). Upon activation, mast cells release several molecules stored in granules, including histamine, 5hydroxytryptamine, tryptase, chymase, prostaglandin D2 (PGD2), and leukotriene B4, trigger ing earlystage allergic responses. [112] [113] [114] Aside from the effect of IgE crosslinking, activation of mast cells is classified as nonallergic and can originate from a diverse range of sources including pathogenassociated molecular pat terns, complement, cytokines, drugs, hormones, and physical stressors such as temperature and pressure. 110, 111 Mast cells can also directly interact with T cells and B cells via antigen presentation and can also be involved in reverse signalling, particularly through CD40 and CD40L ligands. 115 Finally, mast cells have also been shown to mediate signals related to TNFα s timulation in order to control neutrophilic recruitment. 116 
Mast cells and inflammatory conditions
In order to assess the role of mast cells in CPPS, it is useful to draw parallels between their functions in other chronic inflammatory pain disorders and estab lish whether these functions can also be attributed to the development of CPPS. Experimental autoimmune encephalopathy results from a breach of the blood brain barrier, which allows infiltration of immune cells into the central nervous system. 117, 118 Encephalogenic CD4 + IFNγproducing Th1 cells are the major contributor to the pathogenic autoimmune response. 119, 120 IL17a producing Th17 cells and IL9producing Th9 cells have been shown to have major roles in the development of experimental autoimmune encephalopathy. 119, 121 Patients with multiple sclerosis display increases in mast cell numbers at sites of inflammatory demyeli nation, 122 and increased levels of tryptase in their cerebro spinal fluid. 123 In vitro analyses have revealed that mast cell proteases are also capable of degrading myelin, further implicating mast cells and mast cell degranulation in the progression of this debilitating disease. [124] [125] [126] Mast cells are also associated with rheumatoid arthritis, a chronic systemic autoimmune disease that results in loss of mobility and flexibility of synovial joints. 112, 127 Increased numbers of mast cells and secreted tryp tase have been found at affected synovial joints and in synovial fluid, respectively. 128, 129 Increased levels of pro inflammatory cytokines, such as IL6, IL17, and TNFα, have also been associated with rheumatoid arthritis and mast cells have been identified as the main source of IL17 expression. 130, 131 Mast cells have been shown to mediate both T reg and Th17 cells, and are consistently found in close proxi mity to secondary lymphoid organs. 132 The bestdefined mast:T reg cellular interaction is between the OX40 recep tor expressed by T reg and OX40L ligand expressed by mast cells. 133 126, 138 suggesting that, although mast cells are important for the development of CPPS, additional mediators of pain might be present, in both humans and mice, that account for the increased numbers of cytokines and lymphocytes in tissues of affected individuals. Current studies in our laboratory focus on the role of mast cell tryptase in mediating pain in murine EAP, specifically through the protease activated receptor 2 (PAR2) receptor, a potent mediator of innate and adaptive immune responses. 139 These data implicate the PAR2 signalling network as being funda mental for the development of chronic inflammation and pain.
Neuronal mechanisms
Mast cells contribute to rapidly occurring neuronal peripheral sensitization, 140 which is mediated by the neurotrophin nerve growth factor (NGF). [141] [142] [143] Mast cells are known to express TrkA receptors on their cell mem brane and, therefore, NGF binding might cause degranu lation, establishing a feedback mechanism that would promote sensitization mechanisms. As peripheral tissue insults are often associated with some degree of nerve damage, increased levels of NGF might be produced as the tissue regenerates. In men with CPPS, NGF levels are elevated in seminal plasma and directly correlated with pain severity. 144 This intriguing result suggests the existence of underlying peripheral sensitization mecha nisms in CPPS, with NGF and mast cell proteases as potential mediators. Increased NGF expression is known to increase neuronal excitability and enhance neuronal density in peripheral tissues. In this context, previous work has demonstrated increased neuronal density in prostate tissue sections from animal models of prosta titis. 57 These results suggest that peripheral sensitization mediated through NGF (and potentially involving mast cell activation) might underlie chronic pelvic pain.
In addition to, or as a consequence of, persistent periph eral neuronal activation, it is thought that changes in the spinal cord might occur in places where persistent acti vation of spinal cord neurons enhances pain responses. Persistent activation causes alteration in the dorsal horn of the spinal cord, where nociceptor paths enter the central nervous system. Changes include enhanced expression of neurotransmitter receptors (such as Nmethyld aspartate receptor), increased neurotransmitter bio synthesis and release, and the sprouting of nociceptor neurons. 145 Sustained nociceptor firing results in progres sive amplification of dorsal horn neuron activity, which can either remain restricted to the activated synapse or spread to adjacent synapses. This hypersensitivity of dorsal horn neurons can mediate pain after the peripheral damage has healed. Thus, central sensitization within the spinal cord of patients with CPPS could mediate pain long after the resolution of any prostate inflammation or other pelvic insult that might initiate symptoms.
Conclusions
CPPS is a complex syndrome of unknown aetiology; thus, uncovering and implementing effective treatments has so far proven difficult. It is our hypothesis, however, that an initiating event, such as a bacterial infection, acti vates the prostatic immune response in an unchecked manner. A large amount of evidence suggests that loss of regulation of autoreactive T cells has a fundamental role in driving pathogenesis. This loss of regulation amounts to a breaking of tolerance to normal prostatic antigens (self, bacterial, or otherwise), further exacer bation of an adaptive proinflammatory immune response, and develop ment of neural sensitization. We propose that these events are mediated through mast cells, by a variety of cytokines, chemokines, and cellular effectors such as tryptase. Activation of these responses can prevent normal regulation of activated T cells, resulting in auto immunity and unchecked inflammation, e specially in a genetically susceptible host. An open question that remains, however, relates to the role of neural sensitiza tion. Although we, and others, think this effect is also likely to be driven by mast cells, given the chronic nature of patient pain, it is not yet known whether removal of the inflammatory stimulus can reverse neural changes. Resolving these issues would improve our understanding of therapies for men with CPPS, which we believe should focus, at least in part, on restoration of immune balance and tolerance within the prostate.
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